Brighton Jones LLC Buys 46 Shares of Stryker Co. (NYSE:SYK)

Brighton Jones LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 1.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,722 shares of the medical technology company’s stock after purchasing an additional 46 shares during the period. Brighton Jones LLC’s holdings in Stryker were worth $1,114,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in SYK. Keybank National Association OH grew its position in Stryker by 3.5% in the third quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock valued at $7,603,000 after acquiring an additional 952 shares during the period. Carnegie Capital Asset Management LLC boosted its position in Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after buying an additional 497 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Stryker by 3.9% in the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after acquiring an additional 191 shares in the last quarter. Consolidated Planning Corp acquired a new stake in Stryker during the 4th quarter valued at $205,000. Finally, Meritage Portfolio Management acquired a new stake in shares of Stryker in the fourth quarter valued at $569,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a report on Wednesday. UBS Group increased their price objective on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research report on Wednesday. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Roth Mkm boosted their price objective on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Citigroup lifted their price target on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $357.05.

Stryker Price Performance

Shares of NYSE SYK opened at $328.14 on Thursday. The firm has a market cap of $124.85 billion, a P/E ratio of 37.46, a price-to-earnings-growth ratio of 2.71 and a beta of 0.91. The business’s 50 day moving average is $348.05 and its 200-day moving average is $316.78. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.44% and a net margin of 16.03%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.14 EPS. Equities research analysts predict that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a dividend of $0.80 per share. The ex-dividend date was Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.98%. Stryker’s payout ratio is presently 36.53%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.